Notably, Trop-2 is highly expressed in over 80% of triple-negative breast cancers (TNBC) (13) and is associated with enhanced tumor proliferation, invasion, metastasis, and poor prognosis, making it an attractive target for ADCs development (14). Here, TACSTD2 is linked to neoplasm.